Name (Synonyms) | Correlation | |
---|---|---|
drug1153 | INOpulse Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described. The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital.
Description: assessed by 0-10 Borg scale
Measure: Assessment of dyspnea Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by lung CT scan
Measure: Description of pulmonary lesions as assessed by lung CT scan Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by lung CT scan
Measure: Development of pulmonary fibrosis as assessed by lung CT scan Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by incidence of cardiovascular events, venous thromboembolism, and transthoracic echocardiogram
Measure: Incidence or worsening of cardiovascular diseases Time: 3 to 6 months after Sars coV 2 infectionDescription: renal function and urinary parameters
Measure: Incidence or worsening of renal disease Time: 3 to 6 months after Sars coV 2 infectionDescription: hepatic blood parameters
Measure: Incidence or worsening of liver disease Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale: Generalized Anxiety Disorder-7 (GAD7)
Measure: Incidence or worsening of psychological pathology : anxiety Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scales: Patient Health Questionnaire-9 (PHQ9)
Measure: Incidence or worsening of psychological pathology: depression Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale : Post-traumatic Checklist for DSM-5 (PCL-5)
Measure: Incidence or worsening of psychological pathology: post-traumatic stress Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale : insomnia severity index (ISI)
Measure: Incidence or worsening of psychological pathology: insomnia Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by validated scale (EQ-5D-L questionnaire)
Measure: Assessment of the health-related quality of life Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by the fatigue severity sale
Measure: Assessment of the fatigue Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by the Evaluation of Deprivation and Inequalities in Health Examination (EPICES) scale
Measure: Assessment of the socioeconomic deprivation Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by blood glucose level, HbA1C, lipid blood tests, TSH, T3, T4, antithyroperoxydase antibodies, cortisol, ACTH, renin, aldosteron, albumin level, vitamin D level, iron status, weight changes
Measure: development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein
Measure: Development of auto-immune disorders Time: 3 to 6 months after Sars coV 2 infectionDescription: Presence and levels of anti-SARS-CoV-2 antibodies of IgG, IgA and IgM isotypes
Measure: Assessment of the evolution of the humoral anti-SARS-CoV-2 immunization profile Time: 3 to 6 months after Sars coV 2 infectionDescription: assessed by the International Physical Activity Questionnaire (IPAQ)
Measure: Patients' self-reported level of physical activity Time: 3 to 6 months after Sars coV 2 infection